PANREAC presents a new line of excipients for the pharmaceutical industry according to the IPEC guide
PANREAC specialized in the manufacturing of reagents for laboratory analysis, excipients and bulk chemicals to be used as raw materials in the pharmaceutical, cosmetic and food industries.
PANREAC, since its founding in 1941 is one of the Spanish leading companies specialized in the manufacturing of reagents for laboratory analysis, excipients and bulk chemicals to be used as raw materials in the pharmaceutical, cosmetic and food industries.
PANREAC has become a benchmark company in the pharmaceutical manufacturing process for their high quality standards established from the start. Since the company’s beginnings, they offered high purity products PRS for Pharmaceutical applications, becoming later the “PRS-CODEX’, an important level of commitment with the main pharmacopeias. Over last year they have launched a new line of excipients for the pharmaceutical industry fulfilling the guidelines of IPEC.
At the moment, Panreac Pharma counts with more than 300 raw materials for the pharmaceutical and biotechnology industry to be used as excipients or during the manufacturing process.
High Standards of Quality
The excipients are the main ingredient of the medicines in terms of volume and weight; therefore, they have an important function on the final product. For this reason, PANREAC has adopted the IPEC-PQG GMP guide for pharmaceutical excipients (2006), to ensure product consistent conformity through and integral control policy which Panreac has integrated into its manufacturing processes.
The line has an incredible detailed process description including registration, validation and release procedures and also supports supplier audits, upstream and downstream traceability and has a production sample storage. Furthermore, PANREAC has trained specialized workforce to assure the best quality and safety for the pharmaceutical industry and its potential consumers, offering maximum purity, reliability and a firm commitment to society that is finally translated into success and progress. PANREAC has built an exclusive “Clean Room Panreac Pharma” aimed just to develop excipients within strict work conditions in terms of hygiene and contamination control.
PANREAC also disposes of the ISO 9001:2008 on quality management, ISO 14002:2004 on environmental protection and OHSAS 18001:2007 on the safety and health at work, three more commitments that justify one of their main company values: be at the leading edge of quality assurance in the sector.
Fast market development
For seven decades PANREAC has succeed in satisfying the needs of their costumers thanks to their extensive experience, their constant product innovation and quality research.
Thereby, in order to respond the constant increasing market demands, PANREAC disposes of a 15000 m2 high-tech production plant near Barcelona that allows them to optimize flexibility and efficiency in their production. Moreover, since 2008 they developed a new 8000 m2 technologically equipped warehouse to provide the best service to customers and distributors.
Particularly, the company has worked hard to truly expand their products and services internationally. So, for this reason, in 1999 they opened their first two subsidiaries in France and Portugal. Lately in 2007 PANREAC bought the Italian company Nova Chimica, allowing them to get faster in the European market. In 2010 Panreac became part of the chemical division (performance polymers and fluids group) of Illinois Tool Works (ITW), an $18 billion per year U.S. industrial conglomerate.
Nowadays, PANREAC exports their products to more than 80 countries in the world, thanks to their growing and expanding distribution network.
Related News
-
News Strategies for managing an outsourcing partner
Robust oversight linked to increased efficiency and better communication with outsourcing partners. -
News Updated: CPHI North America 2022 Blog
Follow along for live updates from CPHI North America, taking place in Philadelphia, PA from May 17-19. -
News Greater standardisation needed for effective ESG reporting - Expert panel
Increased transparency and standardisation in ESG reporting frameworks is emerging as a key requirement for investors. -
News MedPharm: Increased investment driving developments in topical drugs market
We caught up with MedPharm at CPHI North America to discuss opportunities in the topical and transdermal products space. -
News Pharmapack Awards 2022: Winners Revealed
The jury assessed a wide range of industry-changing innovations in packaging and drug delivery, ultimately selecting seven winners. -
News What it means to be 'At the heart of Pharma'
Informa Markets colleagues explain the motivations behind CPHI’s rebrand. -
News CPhI Podcast Series: Leveraging data science for sustainable autoinjector development
Environmental impact is an area of increasing focus for the pharma and biopharma industries, with companies like Merck, Pfizer and GlaxoSmithKline setting ambitious targets for carbon neutrality and laying plans for waste reduction. -
News Thermo Fisher and Charles River join consortium using robotics to produce cell therapies at scale
The Consortium aims to increase the scale of cell therapy manufacturing to a level impossible with current manual processes.
Position your company at the heart of the global Pharma industry with a CPhI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPhI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance